SynBioBeta Speaker
Celine Schiff-Deb
MISTA | Givaudan
CSO
Céline has been working for 25 years at the interface of science and business, translating biotech innovations into relevant commercial products and services in the areas of food, feed, specialty chemicals, ag and cosmetics. She has been MISTA Chief Science Officer for the last 4 years. Before, she led Product Innovation and Emerging Businesses for multiple biotech platforms including Solazyme/TerraVia/Corbion using microalgae to produce tailored oils and Calysta using bacteria to upgrade methane to proteins. Céline is an Agronomist by training and has a PhD in plant breeding and molecular biology. She spent her first 7 years as a consultant in France at Alcimed advising biotech companies on their marketing and strategy.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Celine
This Year
•
-
From Feedstock to Fork: De-Risking Bio-Based Foods at Industrial Scale
Bio-based food innovation rarely fails in the lab. It fails in the transition to scale. Between pilot success and commercial launch lie the hardest problems in food: reliable feedstocks, waste stream integration, regulatory approval, capital intensity, and infrastructure built for yesterday’s products. This session brings together leaders across law, industrial food systems, waste valorization, and next-generation proteins to examine what it actually takes to move biological food innovations from concept to shelf. Panelists will explore where risk truly accumulates in bio-based food development, how incumbents and startups navigate scale differently, and why waste streams, compliance strategy, and supply chain design often matter more than the underlying biology. The result is a grounded conversation about what survives real-world constraints, not just what sounds compelling on paper.
Purchase Pass
•
-
From Feedstock to Fork: De-Risking Bio-Based Foods at Industrial Scale
Bio-based food innovation rarely fails in the lab. It fails in the transition to scale. Between pilot success and commercial launch lie the hardest problems in food: reliable feedstocks, waste stream integration, regulatory approval, capital intensity, and infrastructure built for yesterday’s products. This session brings together leaders across law, industrial food systems, waste valorization, and next-generation proteins to examine what it actually takes to move biological food innovations from concept to shelf. Panelists will explore where risk truly accumulates in bio-based food development, how incumbents and startups navigate scale differently, and why waste streams, compliance strategy, and supply chain design often matter more than the underlying biology. The result is a grounded conversation about what survives real-world constraints, not just what sounds compelling on paper.
Purchase Pass
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
